NTLA Intellia Therapeutics, Inc.
Q3 2025 10-Q
Filed: Nov 6, 2025Period ending Sep 30, 2025
Health Care
In Vitro & In Vivo Diagnostic SubstancesSEC EDGAR Intellia Therapeutics, Inc. (NTLA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
AI Filing AnalysisQ3 2025 10-Q
Risk Factors
- • New clinical hold risk: FDA placed hold on MAGNITUDE and MAGNITUDE-2 Phase 3 trials for ATTR amyloidosis after Grade 4 liver events and patient death
- • Most updated risk: Delays in clinical development due to evolving FDA requirements and additional preclinical data demands for CRISPR therapies
Get deeper insights on Intellia Therapeutics, Inc.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.